We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Ingested Dual Balloon Encourages Weight Loss

By HospiMedica International staff writers
Posted on 12 Aug 2015
Image: The ReShape Integrated Dual Balloon System (Photo courtesy of ReShape Medical).
Image: The ReShape Integrated Dual Balloon System (Photo courtesy of ReShape Medical).
A novel non-surgical weight loss procedure aids people who either do not want or do not qualify for bariatric surgery.

The ReShape Integrated Dual Balloon System consists of two connected balloons that occupy space in the stomach, so that patients feel satiety with smaller portions of food. The system is inserted via an endoscopic procedure; once in place, the two balloons are inflated using saline, and remain in the stomach for six months to help reduce hunger. During these first six months, and for the six months after the balloons are removed, patients receive comprehensive counseling and support services that include frequent in-office coaching sessions.

The ReShape provides a personalized pathway broken down into three phases over the 12 months. The first phase involves a personalized evaluation and education session. The two balloons are then inserted in the stomach in a 20 minute procedure. This is followed by personalized coaching, with a focus on healthy eating, exercise, and lifestyle habits, to maximize treatment success. The balloons are removed at six months, with six monthly sessions continuing onwards thereafter to set goals and track progress.

To help patients monitor their progress, a ReShape Patient Portal provides weight logging, food logging, activity tracking, goal setting, articles and recipes, community forums, and other important reminders. The portal can be accessed from a smartphone or tablet, and the Fitbit (San Francisco, CA, USA) wireless scale and activity tracker can be integrated as well to integrate all weight loss data in one place.

The ReShape Integrated Dual Balloon System is a product of ReShape Medical (San Clemente, CA, USA), and has been approved by the US Food and Drug Administration (FDA). It is indicated for weight reduction when used in conjunction with diet and exercise, in obese patients with a body mass index (BMI) of 30–40 kg/m2, one or more obesity-related comorbidity conditions, and who have failed weight reduction with diet and exercise alone.

“Many Americans have struggled with a lack of effective weight loss options when their BMI is in the 30–40 range,” said John Morton, MD, MPH, president of the American Society for Metabolic and Bariatric Surgery (Gainesville, FL, USA). “Options like ReShape address a significant gap that exists between diet and exercise, weight loss medications and surgery, offering a minimally invasive, reversible option which we hope will promote long-term healthy habits.”

Related Links:

ReShape Medical
Fitbit
American Society for Metabolic and Bariatric Surgery


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Radial Artery Compression Device
TR Band
New
Ultrasonic Dissector
SONICBEAT

Channels

Critical Care

view channel
Image: Researchers have taken a major step toward cuff-free blood pressure monitoring (Photo courtesy of Gwyneth Moe/Boston University)

Cuff-Free Blood Pressure Monitoring Device to Improve Early Detection and Management of Hypertension

Hypertension affects nearly half of all adults in the U.S. and remains the leading cause of cardiovascular disease. Regular and accurate blood pressure monitoring is essential for managing this condition,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more